Watanabe Takayoshi, Mizuno Hayato Laurence, Norimatsu Jumpei, Obara Takumi, Cabral Horacio, Tsumoto Kouhei, Nakakido Makoto, Kawauchi Daisuke, Anraku Yasutaka
Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Department of Biochemistry and Cellular Biology, National Center of Neurology and Psychiatry (NCNP), Tokyo 187-8551, Japan.
Polymers (Basel). 2023 Apr 6;15(7):1808. doi: 10.3390/polym15071808.
Medulloblastoma is a life-threatening disease with poor therapeutic outcomes. In chemotherapy, low drug accumulation has been a cause of these outcomes. Such inadequate response to treatments has been associated with low drug accumulation, particularly with a limited cellular uptake of drugs. Recently, the conjugation of drugs to ligand molecules with high affinity to tumor cells has attracted much attention for enhancing drug internalization into target cells. Moreover, combining tumor-targeting ligands with nano-scaled drug carriers can potentially improve drug loading capacity and the versatility of the delivery. Herein, we focused on the possibility of targeting CD276/B7-H3, which is highly expressed on the medulloblastoma cell membrane, as a strategy for enhancing the cellular uptake of ligand-installed nanocarriers. Thus, anti-CD276 antibodies were conjugated on the surface of model nanocarriers based on polyion complex micelles (PIC/m) via click chemistry. The results showed that the anti-CD276 antibody-installed PIC/m improved intracellular delivery into CD276-expressing medulloblastoma cells in a CD276-dependent manner. Moreover, increasing the number of antibodies on the surface of micelles improved the cellular uptake efficiency. These observations indicate the potential of anti-CD276 antibody-installed nanocarriers for promoting drug delivery in medulloblastoma.
髓母细胞瘤是一种威胁生命的疾病,治疗效果不佳。在化疗中,药物积累不足一直是导致这些结果的原因。对治疗的这种不充分反应与药物积累不足有关,特别是药物的细胞摄取有限。最近,将药物与对肿瘤细胞具有高亲和力的配体分子偶联,在增强药物内化到靶细胞方面引起了广泛关注。此外,将肿瘤靶向配体与纳米级药物载体相结合可能会提高药物负载能力和递送的多功能性。在此,我们专注于靶向在髓母细胞瘤细胞膜上高表达的CD276/B7-H3的可能性,作为增强安装配体的纳米载体细胞摄取的策略。因此,通过点击化学将抗CD276抗体偶联在基于聚离子复合物胶束(PIC/m)的模型纳米载体表面。结果表明,安装抗CD276抗体的PIC/m以CD276依赖性方式改善了向表达CD276的髓母细胞瘤细胞的细胞内递送。此外,增加胶束表面抗体的数量提高了细胞摄取效率。这些观察结果表明安装抗CD276抗体的纳米载体在促进髓母细胞瘤药物递送方面的潜力。